The DPP9 Knockout Jurkat Polyclonal Cells are a heterogeneous population of Jurkat T lymphoblasts featuring CRISPR/Cas9-mediated disruption of the DPP9 gene. By delivering Cas9 and a DPP9-targeting guide RNA, a diverse array of loss-of-function alleles is generated across the culture, producing a polyclonal pool that minimizes clonal artifacts and preserves population-level complexity. This model enables rapid investigation of DPP9-dependent pathways without the need for single-cell cloning.
The parental Jurkat cell line, derived from the peripheral blood of a 14-year-old male with acute T cell leukemia, is an extensively characterized model for T cell biology. Jurkat cells are widely employed to dissect TCR signal transduction, cytokine networks, and apoptotic mechanisms, making them an ideal chassis for gene-editing studies aimed at understanding both normal immune function and leukemogenesis.
DPP9 is a serine protease that removes N-terminal dipeptides from substrates including the chemokine CXCL12 and the neuropeptides NPY and GLP-1. Critically, DPP9 acts as a gatekeeper of the NLRP1 inflammasome: it directly binds the NLRP1 protein, thereby inhibiting its spontaneous oligomerization and downstream activation of ASC and caspase-1. This regulation is modulated by SUMO1. DPP9 expression is induced by IFN-?? and activated by TCR signaling, linking T cell activation to inflammasome control. DPP9 also interacts with CARD8 and filamin A (FLNA), linking its activity to cytoskeletal dynamics and chemokine processing. Through these interactions, DPP9 influences peptide turnover, inflammatory responses, and cell migration.
In the Jurkat context, DPP9 disruption relieves NLRP1 inhibition, leading to elevated caspase-1 activation and IL-1?? secretion upon inflammasome stimulation. This knockout model also allows examination of how DPP9 loss impacts TCR-proximal signaling events and cytokine gene expression. Moreover, the altered cleavage of CXCL12 may perturb T cell migratory behavior, while the leukemic origin of the host cells provides a relevant setting for assessing DPP9??s role in malignant transformation and immune surveillance evasion.
Researchers can leverage these polyclonal knockout cells for functional assays including Western blotting for DPP9 expression, flow cytometric analysis of T cell activation markers (e.g., CD69, CD25), ELISA quantification of IL-1?? release, caspase-1 enzymatic activity measurements, and RT-qPCR profiling of NLRP1, CARD8, and downstream effectors. Peptide cleavage assays and cell viability tests further enable assessment of DPP9 as a therapeutic target in autoinflammatory diseases and leukemia. For further technical details or ordering inquiries, please contact Ascent Research.
